Nurse practitioners and physician assistants who complete 24 hours of training can obtain a waiver from the Drug Enforcement Agency, allowing them to prescribe
buprenorphine to treat up to 30 patients a year.
The Food and Drug Administration has approved an extended-release, subcutaneous injection formulation of
buprenorphine for use in treating moderate to severe opioid use disorder (OUD), the manufacturer of the drug has announced.
With an expected US launch in Q1 2018, SUBLOCADE (
buprenorphine extended- release) injection for subcutaneous use (CIII) is the first and only once-monthly injectable
buprenorphine formulation for the treatment of moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a transmucosal
buprenorphine-containing product followed by dose adjustment for a minimum of seven days.
CHICAGO -- Methadone was associated with a fourfold higher incidence of neonatal abstinence syndrome (NAS), compared with
buprenorphine for opioid maintenance therapy taken during pregnancy, a retrospective study of 204 neonates reveals.
Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) with Priority Review designation for CAM2038, an investigational
buprenorphine weekly and monthly depot injection for the treatment of adults with opioid use disorder (OUD).
In both inpatient and outpatient settings, medications used for opioid detoxification include
buprenorphine, clonidine, and methadone administered in doses tapered over 5 to 7 days.
SAN FRANCISCO -- The phase III, single-center Blinded
Buprenorphine or Neonatal Morphine Solution (BBORN) clinical trial has established the efficacy of
buprenorphine as an alternative to morphine for treatment of newborns with neonatal abstinence syndrome (NAS).
Buprenorphine appears to have a longer duration of action and minimal adverse effects when compared to other opioids in American kestrels (Falco sparverius).
Buprenorphine hydrochloride is a semisynthetic highly lipophilic opioid derived from thebaine, an opium alkaloid related to morphine.
3,4) In Vermont, for example, more than 500 patients are on waiting lists to receive
buprenorphine (the partial opioid agonist used to treat opioid addiction)--a wait that for many of them will last for more than a year and may cost them their life.
Zubsolv is an advanced formulation of
buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery.
Buprenorphine ingestions might be asymptomatic or can cause drowsiness, vomiting, or respiratory depression, which if untreated can result in death (3).
